Drugs / V540B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06623409 | Nov 2024 → May 2028 expected | — | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V540B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06623409 ↗ |
| Modality | Vaccine | “The study vaccine (called V540B) is designed to protect against the same HPV types that G9 protects against plus other HPV types.” NCT06623409 ↗ |